Amicus Therapeutics Acquires Scioderm for $847,000,000

  • Feed Type
  • Date
    8/31/2015
  • Company Name
    Scioderm
  • Mailing Address
    1007 Slater Road Durham, NC 27703 USA
  • Company Description
    The core business focus of Scioderm is the development of innovative dermatological drugs. Our strategy is to in-license or acquire early to mid-stage pharmaceutical products with the intent to develop the topical products.
  • Website
    http://www.sderm.com
  • Transaction Type
    M&A
  • Transaction Amount
    $847,000,000
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    The $229 million upfront payment for Scioderm consists of $125 million in cash and $104 million in Amicus stock. Amicus will pay Scioderm shareholders another $361 million in cash or stock upon achievement of certain clinical and regulatory milestones and $257 million in cash or stock upon achievement of certain sales milestones.

Trending on Xconomy